WP5 covers the translational and innovative aspects of clinical research and hence will liaise with biotech and pharma to promote the potential of ERNs for the conduct of clinical trials in the rare disease field.

This WP aims to support the process of translating the discoveries made in the clinic and laboratory into new diagnostic and therapeutic interventions for rare diseases. This process is highly complex, costly and time-consuming, with high failure rates. Successful translation requires both interdisciplinary and inter-sectoral collaboration, as well as access to cutting edge analytical technologies, preclinical models and assays, and bio-samples and data. In light of foregoing, WP5 has as its objective to support the ERNs’ collective ability to develop knowledge into patient benefit.